WAYNE, Pa., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) will be presenting at the Morgan Stanley 23rd Annual Global Healthcare Conference at the Sheraton New York Times Square, on Tuesday, September 9, 2025, at 3:20 p.m. (ET). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to im ...

Core Insights - Teleflex Incorporated reported solid second quarter results with an increase in constant currency revenue growth and adjusted earnings per share compared to the prior year [3][6] - The company successfully completed the acquisition of BIOTRONIK's Vascular Intervention business, which positively impacted the 2025 adjusted constant currency revenue guidance [3][9] - The company is focused on unlocking value through the separation of NewCo and exploring options to maximize shareholder value [3] Financial Performance - For the three months ended June 29, 2025, consolidated net revenue was $780.9 million, reflecting a 4.2% increase compared to $749.7 million in the prior year [5][6] - Adjusted diluted earnings per share from continuing operations for the second quarter was $3.73, up from $3.42 in the prior year [6][10] - The company raised its full year 2025 GAAP revenue growth guidance to a range of 9.00% to 10.00% and adjusted constant currency revenue growth guidance to 7.70% to 8.70% [9][10] Revenue by Segment - In the Americas, net revenue for the three months ended June 29, 2025, was $525.7 million, a 1.9% increase from $515.6 million in the prior year [5] - EMEA segment revenue increased by 13.0% to $166.2 million, while Asia segment revenue grew by 2.3% to $89.0 million [5] - For the six months ended June 29, 2025, consolidated net revenue was $1,481.6 million, a slight decrease of 0.4% compared to $1,487.5 million in the prior year [5][6] Product Category Performance - The Interventional product category saw significant growth, with revenue increasing by 20.4% to $170.0 million for the three months ended June 29, 2025 [8] - Vascular Access revenue grew by 2.4% to $185.5 million, while Anesthesia and OEM categories experienced declines of 6.0% and 11.4%, respectively [8] - For the six months ended June 29, 2025, Interventional revenue increased by 11.5% to $307.6 million, while Anesthesia and OEM categories saw declines of 8.0% and 19.2%, respectively [8][36] Outlook - The company expects the acquisition of the Vascular Intervention business to generate approximately $204 million in revenue in the second half of 2025 [9] - The adjusted diluted earnings per share guidance for 2025 was raised to a range of $13.90 to $14.30, reflecting a year-over-year increase [10][14] - The company anticipates a positive impact of approximately 0.85% from foreign exchange rate fluctuations for the full year [9][11]

Core Points - Teleflex Incorporated will host a conference call to discuss its second quarter financial results and provide an operational update on July 31, 2025 at 8:00 a.m. Eastern Time [1] - An audio replay of the call will be available starting at 11:00 a.m. Eastern Time on the same day [2] - Teleflex is a global provider of medical technologies focused on improving health and quality of life, with a diverse portfolio in various therapy areas [3] - The company is known for its trusted brands such as Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™, and Weck™ [4]

Financial Performance - Company reported net revenues of $700.7 million for the first quarter of 2025, a decrease of 5.0% compared to $737.8 million in the prior year period [8][34] - GAAP diluted earnings per share (EPS) from continuing operations was $2.07, compared to $0.33 in the prior year period [8][46] - Adjusted diluted EPS from continuing operations was $2.91, down from $3.21 in the prior year period [8][46] Revenue by Segment - In the Americas, net revenue was $475.7 million, down 3.7% from $494.0 million [5][34] - EMEA segment reported net revenue of $151.2 million, a decrease of 5.3% from $159.6 million [5][34] - Asia segment saw a decline of 12.4%, with revenues of $73.8 million compared to $84.2 million [5][34] Revenue by Product Category - Vascular Access category reported revenues of $182.4 million, a slight increase of 0.6% from $181.4 million [7][34] - Interventional category revenues increased by 2.1% to $137.5 million from $134.7 million [7][34] - Anesthesia revenues decreased by 10.1% to $86.6 million from $96.4 million [9][34] Guidance and Outlook - Company raised its full-year 2025 revenue growth outlook on a GAAP basis to a range of 1.28% to 2.28% [10][11] - Adjusted diluted EPS guidance for 2025 was lowered to a range of $13.20 to $13.60, down from $13.95 to $14.35 [11][12] - Expected impact from tariffs in 2025 is approximately $55 million, which will be recorded in cost of goods sold [8][11] Strategic Initiatives - Company is evaluating strategies to mitigate exposure to tariffs and remains focused on executing its plan for the year [3] - Plans to separate Teleflex into two independent publicly traded companies, with significant third-party interest in acquiring NewCo [3]

Company Overview - Teleflex Incorporated is a global provider of medical technologies focused on improving health and quality of life [2] - The company aims to become the most trusted partner in healthcare, offering a diverse portfolio in various therapy areas including anesthesia, emergency medicine, interventional cardiology, radiology, surgical, vascular access, and urology [2] Product Portfolio - Teleflex is home to several trusted brands such as Arrow™, Barrigel™, Deknatel™, QuikClot™, LMA™, Pilling™, Rüsch™, UroLift™, and Weck™, all united by a common purpose [3] Upcoming Events - Management of Teleflex will present at the BofA Securities 2025 Health Care Conference on May 14, 2025, at 1:40 p.m. (PT) [1] - A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website [1]